Shanghai's Everest Medicines Stages $451 Million Hong Kong IPO

Everest Medicines of Shanghai completed a $451 million IPO in Hong Kong to develop its portfolio of eight assets in-licensed for China development. The company's stock climbed 32% in its first trading session. Founded in 2017, Everest was incubated by CBC Group (formerly C-Bridge Capital) to be its China in-licensing company. The company's eight products address needs in oncology, immunology, cardio-renal and infectious diseases, several of which are in late-stage development or have filed for approval. More details.... Stock Symbol: (HK:1952) Share this with colleagues: // //